Dr. Rony Dahan
The ability of antibodies to detect pathogens and malignant cells, and trigger diverse immune effector functions make them central players in the immune response. Monoclonal antibodies have turned into a powerful drug platform at the front of cancer immunotherapy approaches. Our group studies the mechanisms that control the activity of both natural and therapeutic antibodies.
We are particularly interested in the roles of the Fc regions of these antibodies and in their various Fcγ Receptors (FcγRs) in mediating anti-tumor activities,
For maximum clinical relevance we are studying human antibodies in mice humanized for FcγRs and other relevant human genes. We are exploring strategies to enhance the identified pathways and aim to create 2nd generation antibodies with improved activity.